|
|||||||||||||||||
|
> MEDTECH
Feb 8th, 2010
Fluidigm and IntegraGen join forces to create a genetic analysis service and European demonstration lab
Fluidigm, the inventor of integrated fluidic circuits (IFCs), has joined with IntegraGen SA, one of France's leading providers of genetic research testing services, to bring IFC technology to European researchers. IntegraGen will offer premium class services to its customers using the Fluidigm BioMark™ System for Genetic Analysis and the Access Array™ sample preparation system for next-generation sequencing. IntegraGen's lab will also be a demonstration site for European researchers investigating Fluidigm's technology.
Fluidigm, the inventor of integrated fluidic circuits (IFCs), has joined with IntegraGen SA, one of France's leading providers of genetic research testing services, to bring IFC technology to European researchers. IntegraGen will offer premium class services to its customers using the Fluidigm BioMark™ System for Genetic Analysis and the Access Array™ sample preparation system for next-generation sequencing. IntegraGen's lab will also be a demonstration site for European researchers investigating Fluidigm's technology. Fluidigm develops, manufactures and markets proprietary Integrated Fluidic Circuit (IFC) systems that significantly improve productivity in life science research. Fluidigm's IFCs enable the simultaneous performance of thousands of sophisticated biochemical measurements in extremely minute volumes. These "integrated circuits for biology" are made possible by miniaturising and integrating liquid handling components on a single microfluidic device (IFC). Fluidigm's systems, consisting of instrumentation, software and single-use chips, increase throughput, decrease costs and enhance sensitivity compared to conventional laboratory systems. Fluidigm products are only available for research use. For more information, please visit www.fluidigm.com. IntegraGen is dedicated to gene discovery and the commercialization of molecular diagnostics products and services that provide clinicians with new tools to personalize diagnosis, treatment, and therapy. IntegraGen is focused on the prevention and proactive management of complex debilitating diseases, and dedicated to addressing the needs of patients, clinicians, and advocacy groups. With discovery and intellectual property focused on diabetes, obesity, bipolar disorders, schizophrenia, and autism, IntegraGen's Core Strategy is to deliver a portfolio of high-value molecular diagnostic products and services that drive personalized healthcare solutions for complex diseases. The Genetic Services Business provides Genotyping Services to the research community. For more information, please visit www.integragen.com. Sources :
More MEDTECH news Feb 4th
Feb 1st
Jan 30th
Jan 27th
Jan 26th
|
||||||||||||||||
©2007 Yole Developpement All rights reserved Disclaimer | Legal notice | To advertise
Yole Développement: 45 rue Sainte Geneviève, F-69006 Lyon, France. TEL: (33) 472 83 01 80 FAX: (33) 472 83 01 83 E-Mail: info @yole.fr |
|||||||||||||||||